See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus

Ave Talu

https://www.etis.ee/CV/Ave_Talu/est
ave.talu@gmail.com
D-7677-2014

Teenistuskäik

Töökohad ja ametid
01.05.2013–...   
University of Tartu, Tartu Ülikool (1,00)
2001–2013   
Tervise Arengu Instituut, Eesti Uimastiseire Keskus, juhataja (1,00)
 
 
Haridustee
2004–2008   
Tartu Ülikool, teadusmagistri kraad rahvatervise erialal (MScPH), õppekavajärgne spetsialiseerumine: epidemioloogia ja biostatistika
1992–1996   
Tallinna Pedagoogikaülikool, sotsiaaltöö
1991–1995   
Tallinna Pedagoogikaülikool, eelkooli pedagoogika ja psühholoogia õpetaja

Kvalifikatsioon

Teaduskraadid
Ave Talu, magistrikraad (teaduskraad), 2008, (juh) Mati Rahu; Anneli Uusküla, Illegaalsete uimastite tarvitamine ja kättesaadavus Eestis: tähendus HIVi levimuse ja preventsiooni seisukohalt, Tartu Ülikool, Arstiteaduskond.
 
 
Teaduspreemiad ja tunnustused
2006, Ave Talu, Fogarty stipendium HIV/AIDSi uuringute alal, AITRP, NIH, USA, New York, National Development and Research Institutes, Inc. (NDRI)
2002, Ave Talu, Pompidou Group Fellowship under the Pompidou Group Fellowship Scheme for Studies and Research in Drug Abuse , University of London, Imperial College of Science, Technology and Medicine (London) and University of Manchester, UK
 
 
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.6. Rahvatervishoid

Publikatsioonid

1.1. Teadusartiklid, mis on kajastatud Web of Science andmebaasides Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index, Emerging Sources Citation Index ja/või andmebaasis Scopus (v.a. kogumikud)
 
Uusküla A, Talu A, Vorobjov S, Salekešin M, Rannap J, Lemsalu L, DesJarlais, D (2020). The fentanyl epidemic in Estonia: factors in its evolution and opportunities for a comprehensive public health response, a scoping review. International Journal of Drug Policy, 81. DOI: 10.1016/j.drugpo.2020.102757.
 
Des Jarlais, Don; Uuskula, Anneli; Talu, Ave; Barnes, David M; Raag, Mait; Arasteh, Kamyar; Org, Greete; Demarest, Donna; Feelemyer, Jonathan; Berg, Hayley; Tross, Susan (2019). Implementing an Updated "Break the Cycle" Intervention to Reduce Initiating Persons into Injecting Drug Use in an Eastern European and a US "opioid epidemic" Setting. AIDS and Behavior, 23 (9), 2304−2314. DOI: 10.1007/s10461-019-02467-y.
 
Anneli Uusküla, Mait Raag, Kristina Marsh, Ave Talu, Sigrid Vorobjov, Don Des Jarlais (2017). HIV prevalence and gender differences among new injection-drug-users in Tallinn, Estonia: A persisting problem in a stable high prevalence epidemic. PLoS ONE, 12 (2), e0170956. DOI: 10.1371/journal.pone.0170956.
 
Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLoS ONE, 11 (6), e0156850−e0156850. DOI: 10.1371/journal.pone.0156850.
 
Zabransky, T.; Mravcik, V.; Talu, A.; Jasaitis, E. (2014). Post-Soviet Central Asia: a summary of the drug situation. International Journal of Drug Policy, 25, 1186−1194.10.1016/j.drugpo.2014.05.004.
 
Mravcik, V; Zabransky, T; Talu, A; Jasaitis, E; Gafarova, N; Musabekova, Z; Baymirova, L; Makhsutov, M; Ganiev, F. (2014). http://www.sciencedirect.com/science/article/pii/S0955395914000681. International Journal of Drug Policy, 25 (6), 1215−1220.10.1016/j.drugpo.2014.03.007.
 
Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66 (3), 239−244.10.1097/QAI.0000000000000127.
 
Rüütel, Kristi; Karnite, Anda; Talu, Ave; Abel-Ollo, Katri; Kirvelaite, Gunta; Kliiman, Kai; Loit, Helle-Mai; Uusküla, Anneli. (2014). Prevalence of IGRA-positivity and risk factors for tuberculosis among injecting drug users in Estonia and Latvia. International Journal of Drug Policy, 25 (1), 175−178.10.1016/j.drugpo.2013.10.002.
 
Huik, K; Avi, R; Carrillo, A; Harper, N; Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 8 (7), e70561.10.1371/journal.pone.0070561.
 
Uusküla, Anneli; Rajaleid, Kristiina; Talu, Ave; Abel-Ollo, Katri; Des Jarlais, Don (2013). A decline in the prevalence of injecting drug users in Estonia, 2005–2009. International Journal of Drug Policy, 24 (4), 312−318.10.1016/j.drugpo.2012.11.002.
 
Vorobjov, S; Des Jarlais, DC; Abel-Ollo, K; Talu, A; Rüütel, K; Uusküla, A (2013). Socio-demographic factors, health risks and harms associated with early initiation of injection among people who inject drugs in Tallinn, Estonia: Evidence from cross-sectional surveys. International Journal of Drug Policy, 24 (2), 150−155.10.1016/j.drugpo.2012.08.003.
 
Uusküla A, Des Jarlais DC, Kals M, Rüütel K, Abel-Ollo K, Talu A, Sobolev I. (2011). Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia. BMC Public Health, 30 (11), 517.10.1186/1471-2458-11-517.
 
Uusküla, A.; McMahon, JM.; Raag, M.; Silm, S.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Ahas, R.; Des Jarlais, DC. (2010). Emergent properties of HIV risk among injection drug users in Tallinn, Estonia: synthesis of individual and neighbourhood-level factors. Sexually Transmitted Infections, 86, 3, 79−84.
 
Uusküla, A.; Johnston, L.G.; Raag, M.; Trummal, A.; Talu, A.; Des Jarlais, D.C. (2010). Evaluating recruitment among female sex workers and injecting drug users at risk for HIV using respondent driven sampling in Estonia. Journal of Urban Health, 87 (2), 304−317.10.1007/s11524-009-9427-7.
 
Talu, A.; Rajaleid, K.; Abel-Ollo, K.; Rüütel, K.; Rahu, M.; Rhodes, T.; Platt, L.; Bobrova, N.; Uusküla, A. (2010). HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn, Estonia: Implications for intervention. International Journal of Drug Policy, 21 (1), 56−63.10.1016/j.drugpo.2009.02.007.
 
Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730−739.
 
Vorobjov, S.; Uusküla, A.; Abel-Ollo, K.; Talu, A.; Des Jarlais, D. (2009). Should pharmacists have a role in harm reduction services for IDUs? A qualitative study in Tallinn, Estonia. Journal of Urban Health, 86 (6), 918−928.
 
Abel-Ollo, K.; Rahu, M.; Rajaleid, K.; Talu, A.; Rüütel, K.; Platt, L.; Bobrova, N.; Rhodes, T.; Uusküla, A. (2009). Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia. AIDS Care, 21 (7), 851−857.
 
Vorobjov, S.; Uuskula, A.; Abel-Ollo, K.; Talu, A.; Ruutel, K.; Des Jarlais, D.C. (2009). Comparison of injecting drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn, Estonia. Harm reduction journal, 6 (1), 3.
 
Uusküla, A.; Kals, M.; Rajaleid, K.; Abel, K.; Talu, A.; Rüütel, K.; Platt, L.; Rhodes, T.; Dehovitz, J.; Des Jarlais, D. (2008). High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. Journal of Public Health, 30 (2), 119−125. DOI: 10.1093/pubmed/fdn014.
 
Uusküla, A.; Rajaleid, K.; Talu, A.; Abel, K.; Rüütel, K.; Hay, G. (2007). Estimating injection drug use prevalence using state wide administrative data sources: Estonia, 2004. Addiction Research & Theory, 15 (4), 411−424.
 
Platt, L.; Bobrova, N.; Rhodes, T.; Uusküla, A.; Parry, JV.; Rüütel, K.; Talu, A.; Abel, K.; Rajaleid, K.; Judd, A. (2006). High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS, 20 (16), 2120−2123.
2.2. Monograafiad (sisestatud enne 1. juulit 2014. a.)
 
Kalikova, Nelli; Kurbatova, Aljona; Talu, Ave (2002). Estonia : children and adolescents involved in drug use and trafficking: a rapid assessment. Geneva: International Labour Office.
2.3. Dissertatsioonide seerias ilmunud dissertatsioonid (v.a. käsikirjalised);
 
Talu, Ave (2008). Illegaalsete uimastite tarvitamine ja kättesaadavus Eestis: tähendus HIVi levimuse ja preventsiooni seisukohalt [Võrguteavik] : magistritöö rahvatervishoius. (Tartu Ülikool.; Tervishoiu instituut; ). Tartu: Tartu Ülikooli Raamatukogu.
2.5. Projekti, tellitud teadustöö või analüüsi publitseeritud raport
 
Tamm, Gerly; Talu, Ave; Markina, Anna; Villenthal, Anneli; Espenberg, Siim, Tourunen, Jouni; Varblane, Uku (2016). Narkosõltlastest õigusrikkujate sõltuvusravi ja rehabilitatsioon Eestis.
 
Jasaitis, E; Lodwick, A; Mravcik, V; Talu, A; Zabransky, T; Kubatov, A; Khasanov, K; Mokiy, A; Yussopov, O. (2013). 2013 Regional Report on Drug Situation in Central Asia. In: Zabransky, T; A; Mravcik, V. (Ed.). .. Czech Republic.
5.1. Konverentsiteesid, mida kajastab Thomson Reuters Web of Science
 
Rüütel, Kristi; Priimagi, Ljudmilla; Tefanova, Valentina; Tallo, Tatjana; Talu, Ave; Abel-Ollo, Katri; Uuskula, Anneli. (2009). HCV prevalence and risk behaviours among injecting drug users in Estonia. In: Journal of Clinical Virology (S24).European Society for Clinical Virology (ESCV) Winter Meeting, Amsterdam, The Netherlands, January 7-10, 2009. Elsevier Sci.
 
Rüütel, K.; Priimägi, L.; Tefanova, V.; Tallo, T.; Talu, A.; Abel-Ollo, K.; Uusküla, A. (2008). HCV prevalence and risk factors among injecting drug users in Estonia. Journal of Clinical Virology, 44: Programme and abstracts of European Society for Clinical Virology(ESCV), Winter Meeting, Amsterdam, The Netherlands, January 7-10, 2009. S24. (Suppl. 1).
5.2. Konverentsiteesid, mis ei kuulu valdkonda 5.1
 
Uibopuu, H.; Huik, K.; Avi, R.; Pauskar, M.; Kallas, E.; Karki, T.; Krispin, T.; Kool, P.; Schmidt, J.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Lutsar, I. (2012). Viral tropism of HIV-1 CRF06_cpx and its association with CCR5 haplotypes. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.
 
Tefanova, V.; Tallo, T.; Reshetnjak, I.; Kuznetsova, T.; Priimägi, L.; Abel-Ollo, K.; Talu, A. (2011). Molecular epidemiology of HCV in population of IDUs in Estonia. 14th Annual meeting of the ESCV, Funchal, Madeira, 21-24 September 2011, Abstract book.. , 121.
2.07.2020

Ave Talu

https://www.etis.ee/CV/Ave_Talu/eng
ave.talu@gmail.com
D-7677-2014

Career

Institutions and positions
01.05.2013–...   
University of Tartu, University of Tartu (1,00)
01.01.2001–01.04.2013   
National Institute for Health Development, National Institute for Health Development, Estonian Drug Monitoring Centre, Head of EDMC / Head of Estonian Reitox NFP (1,00)
 
 
Education
2004–2008   
University of Tartu, magister scientiarum Public Health (MScPH) , main field of the study for qualification: epidemiology and biostatistics
1992–1996   
Tallinn Pedagogical University, Faculty of Social Science, social work
1991–1995   
Tallinn Pedagogical University, Faculty of Social Science, teacher of pre-school pedagogics and psychology

Qualifications

Academic degrees
Ave Talu, Research Master's Degree, 2008, (sup) Mati Rahu; Anneli Uusküla, Illegaalsete uimastite tarvitamine ja kättesaadavus Eestis: tähendus HIVi levimuse ja preventsiooni seisukohalt (Consumption and availability of illicit drugs in Estonia: its implications for the prevalence and prevention of HIV), University of Tartu, Faculty of Medicine.
 
 
Honours & awards
2006, Ave Talu, Fogarty fellowship (HIV/AIDS research), AITRP, NIH, USA, New York, National Development and Research Institutes, Inc. (NDRI)
2002, Ave Talu, Pompidou Group Fellowship under the Pompidou Group Fellowship Scheme for Studies and Research in Drug Abuse , University of London, Imperial College of Science, Technology and Medicine (London) and University of Manchester, UK
 
 
Fields of research
ETIS CLASSIFICATION: 3. Health; 3.6. Public Health Science

Publications

1.1. Teadusartiklid, mis on kajastatud Web of Science andmebaasides Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index, Emerging Sources Citation Index ja/või andmebaasis Scopus (v.a. kogumikud)
 
Uusküla A, Talu A, Vorobjov S, Salekešin M, Rannap J, Lemsalu L, DesJarlais, D (2020). The fentanyl epidemic in Estonia: factors in its evolution and opportunities for a comprehensive public health response, a scoping review. International Journal of Drug Policy, 81. DOI: 10.1016/j.drugpo.2020.102757.
 
Des Jarlais, Don; Uuskula, Anneli; Talu, Ave; Barnes, David M; Raag, Mait; Arasteh, Kamyar; Org, Greete; Demarest, Donna; Feelemyer, Jonathan; Berg, Hayley; Tross, Susan (2019). Implementing an Updated "Break the Cycle" Intervention to Reduce Initiating Persons into Injecting Drug Use in an Eastern European and a US "opioid epidemic" Setting. AIDS and Behavior, 23 (9), 2304−2314. DOI: 10.1007/s10461-019-02467-y.
 
Anneli Uusküla, Mait Raag, Kristina Marsh, Ave Talu, Sigrid Vorobjov, Don Des Jarlais (2017). HIV prevalence and gender differences among new injection-drug-users in Tallinn, Estonia: A persisting problem in a stable high prevalence epidemic. PLoS ONE, 12 (2), e0170956. DOI: 10.1371/journal.pone.0170956.
 
Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PLoS ONE, 11 (6), e0156850−e0156850. DOI: 10.1371/journal.pone.0156850.
 
Zabransky, T.; Mravcik, V.; Talu, A.; Jasaitis, E. (2014). Post-Soviet Central Asia: a summary of the drug situation. International Journal of Drug Policy, 25, 1186−1194.10.1016/j.drugpo.2014.05.004.
 
Mravcik, V; Zabransky, T; Talu, A; Jasaitis, E; Gafarova, N; Musabekova, Z; Baymirova, L; Makhsutov, M; Ganiev, F. (2014). http://www.sciencedirect.com/science/article/pii/S0955395914000681. International Journal of Drug Policy, 25 (6), 1215−1220.10.1016/j.drugpo.2014.03.007.
 
Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66 (3), 239−244.10.1097/QAI.0000000000000127.
 
Rüütel, Kristi; Karnite, Anda; Talu, Ave; Abel-Ollo, Katri; Kirvelaite, Gunta; Kliiman, Kai; Loit, Helle-Mai; Uusküla, Anneli. (2014). Prevalence of IGRA-positivity and risk factors for tuberculosis among injecting drug users in Estonia and Latvia. International Journal of Drug Policy, 25 (1), 175−178.10.1016/j.drugpo.2013.10.002.
 
Huik, K; Avi, R; Carrillo, A; Harper, N; Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 8 (7), e70561.10.1371/journal.pone.0070561.
 
Uusküla, Anneli; Rajaleid, Kristiina; Talu, Ave; Abel-Ollo, Katri; Des Jarlais, Don (2013). A decline in the prevalence of injecting drug users in Estonia, 2005–2009. International Journal of Drug Policy, 24 (4), 312−318.10.1016/j.drugpo.2012.11.002.
 
Vorobjov, S; Des Jarlais, DC; Abel-Ollo, K; Talu, A; Rüütel, K; Uusküla, A (2013). Socio-demographic factors, health risks and harms associated with early initiation of injection among people who inject drugs in Tallinn, Estonia: Evidence from cross-sectional surveys. International Journal of Drug Policy, 24 (2), 150−155.10.1016/j.drugpo.2012.08.003.
 
Uusküla A, Des Jarlais DC, Kals M, Rüütel K, Abel-Ollo K, Talu A, Sobolev I. (2011). Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia. BMC Public Health, 30 (11), 517.10.1186/1471-2458-11-517.
 
Uusküla, A.; McMahon, JM.; Raag, M.; Silm, S.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Ahas, R.; Des Jarlais, DC. (2010). Emergent properties of HIV risk among injection drug users in Tallinn, Estonia: synthesis of individual and neighbourhood-level factors. Sexually Transmitted Infections, 86, 3, 79−84.
 
Uusküla, A.; Johnston, L.G.; Raag, M.; Trummal, A.; Talu, A.; Des Jarlais, D.C. (2010). Evaluating recruitment among female sex workers and injecting drug users at risk for HIV using respondent driven sampling in Estonia. Journal of Urban Health, 87 (2), 304−317.10.1007/s11524-009-9427-7.
 
Talu, A.; Rajaleid, K.; Abel-Ollo, K.; Rüütel, K.; Rahu, M.; Rhodes, T.; Platt, L.; Bobrova, N.; Uusküla, A. (2010). HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn, Estonia: Implications for intervention. International Journal of Drug Policy, 21 (1), 56−63.10.1016/j.drugpo.2009.02.007.
 
Huik, K.; Sadam, M.; Karki, T.; Avi, R.; Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.; Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730−739.
 
Vorobjov, S.; Uusküla, A.; Abel-Ollo, K.; Talu, A.; Des Jarlais, D. (2009). Should pharmacists have a role in harm reduction services for IDUs? A qualitative study in Tallinn, Estonia. Journal of Urban Health, 86 (6), 918−928.
 
Abel-Ollo, K.; Rahu, M.; Rajaleid, K.; Talu, A.; Rüütel, K.; Platt, L.; Bobrova, N.; Rhodes, T.; Uusküla, A. (2009). Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia. AIDS Care, 21 (7), 851−857.
 
Vorobjov, S.; Uuskula, A.; Abel-Ollo, K.; Talu, A.; Ruutel, K.; Des Jarlais, D.C. (2009). Comparison of injecting drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn, Estonia. Harm reduction journal, 6 (1), 3.
 
Uusküla, A.; Kals, M.; Rajaleid, K.; Abel, K.; Talu, A.; Rüütel, K.; Platt, L.; Rhodes, T.; Dehovitz, J.; Des Jarlais, D. (2008). High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. Journal of Public Health, 30 (2), 119−125. DOI: 10.1093/pubmed/fdn014.
 
Uusküla, A.; Rajaleid, K.; Talu, A.; Abel, K.; Rüütel, K.; Hay, G. (2007). Estimating injection drug use prevalence using state wide administrative data sources: Estonia, 2004. Addiction Research & Theory, 15 (4), 411−424.
 
Platt, L.; Bobrova, N.; Rhodes, T.; Uusküla, A.; Parry, JV.; Rüütel, K.; Talu, A.; Abel, K.; Rajaleid, K.; Judd, A. (2006). High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS, 20 (16), 2120−2123.
2.2. Monograafiad (sisestatud enne 1. juulit 2014. a.)
 
Kalikova, Nelli; Kurbatova, Aljona; Talu, Ave (2002). Estonia : children and adolescents involved in drug use and trafficking: a rapid assessment. Geneva: International Labour Office.
2.3. Dissertatsioonide seerias ilmunud dissertatsioonid (v.a. käsikirjalised);
 
Talu, Ave (2008). Illegaalsete uimastite tarvitamine ja kättesaadavus Eestis: tähendus HIVi levimuse ja preventsiooni seisukohalt [Võrguteavik] : magistritöö rahvatervishoius. (Tartu Ülikool.; Tervishoiu instituut; ). Tartu: Tartu Ülikooli Raamatukogu.
2.5. Projekti, tellitud teadustöö või analüüsi publitseeritud raport
 
Tamm, Gerly; Talu, Ave; Markina, Anna; Villenthal, Anneli; Espenberg, Siim, Tourunen, Jouni; Varblane, Uku (2016). Narkosõltlastest õigusrikkujate sõltuvusravi ja rehabilitatsioon Eestis.
 
Jasaitis, E; Lodwick, A; Mravcik, V; Talu, A; Zabransky, T; Kubatov, A; Khasanov, K; Mokiy, A; Yussopov, O. (2013). 2013 Regional Report on Drug Situation in Central Asia. In: Zabransky, T; A; Mravcik, V. (Ed.). .. Czech Republic.
5.1. Konverentsiteesid, mida kajastab Thomson Reuters Web of Science
 
Rüütel, Kristi; Priimagi, Ljudmilla; Tefanova, Valentina; Tallo, Tatjana; Talu, Ave; Abel-Ollo, Katri; Uuskula, Anneli. (2009). HCV prevalence and risk behaviours among injecting drug users in Estonia. In: Journal of Clinical Virology (S24).European Society for Clinical Virology (ESCV) Winter Meeting, Amsterdam, The Netherlands, January 7-10, 2009. Elsevier Sci.
 
Rüütel, K.; Priimägi, L.; Tefanova, V.; Tallo, T.; Talu, A.; Abel-Ollo, K.; Uusküla, A. (2008). HCV prevalence and risk factors among injecting drug users in Estonia. Journal of Clinical Virology, 44: Programme and abstracts of European Society for Clinical Virology(ESCV), Winter Meeting, Amsterdam, The Netherlands, January 7-10, 2009. S24. (Suppl. 1).
5.2. Konverentsiteesid, mis ei kuulu valdkonda 5.1
 
Uibopuu, H.; Huik, K.; Avi, R.; Pauskar, M.; Kallas, E.; Karki, T.; Krispin, T.; Kool, P.; Schmidt, J.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Lutsar, I. (2012). Viral tropism of HIV-1 CRF06_cpx and its association with CCR5 haplotypes. 10th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, 28 - 30 March 2012 Barcelona Spain.
 
Tefanova, V.; Tallo, T.; Reshetnjak, I.; Kuznetsova, T.; Priimägi, L.; Abel-Ollo, K.; Talu, A. (2011). Molecular epidemiology of HCV in population of IDUs in Estonia. 14th Annual meeting of the ESCV, Funchal, Madeira, 21-24 September 2011, Abstract book.. , 121.
2.07.2020

Otsi projekti

  • {{item.Name}}
Asutus on projekti finantseerija   Asutus on projekti teostaja  
  • {{searchListItem.Name}}
Kõik   Tavaprojektid   Ülemprojektid   Alamprojektid  
Uus Frascati (2015)
Uus ja vana Frascati (otsing uue järgi väljastab ka seotud vanad)
Kõik
Käimasolevad
Lõppenud
Algus
Hajus
Täpne
Lihtotsing Tühjenda
  • Leitud 7 kirjet
ProgrammLiikNumberNimiProjekti algusProjekti lõppVastutav täitjaAsutusFinantseerijapoolne rahastamine
MUUEUSK.METADOON (UNODC)Eesti metadoonasendusravi kvaliteedi ja teenuste vajaduste hindamise uuring01.01.200831.12.2008Katri Abel-OlloTervise Arengu Instituut5 349,28 EUR
SFSF0940026s07Haiguste esinemine ja nende mõjurid Eesti rahvastikus01.01.200731.12.2012Mati RahuTervise Arengu Instituut863 828,32 EUR
MUUMARTH08228 (ESXO-16379-TA08 (CRDF - Civilian Research & Develo)HIV ülekanne narkootikumide kasutajate hulgas Tallinnas, Eestis01.01.200931.12.2009Katri Abel-OlloTervise Arengu Instituut35 726,61 EUR
MUU3.2.AK-1/205 (2005305/3)HIV-nakkuse ning teiste infektsioonide ja riskikäitumise levimus süstivate narkomaanide ja nende peamiste sekspartnerite seas01.01.200731.12.2007Helle-Mai LoitTervise Arengu Instituut338 277,96 EUR
SFSF0940006s12Krooniliste haiguste epidemioloogia: geen-keskkonnast, elustiilist ja psühhosotsiaalsetest mõjuritest tingitud riskitegurite kujunemine ning riskikäitumine01.01.201231.12.2014Toomas VeidebaumTervise Arengu Instituut300 300,00 EUR
MUUEUSK.GF-TAISüstivate narkomaanide levimus Eesti rahvastikus, 200501.01.200531.12.2005Ave TaluTervise Arengu Instituut4 665,55 EUR
MUUEUSK.APTEEKSüstivatele narkomaanidele suunatud apteegi põhiste riskikäitumist vähendavate teenuste võimalikkuse kaardistamine01.01.200831.12.2008Sigrid VorobjovTervise Arengu Instituut3 782,42 EUR